A post by Jimmy667 addressing the FUD about the Cytodyn s-3 and the conversion of the Fife debt:
“ If there is no default on the loan from Fife the rachet clause is no triggered. The loan is not in default. The rachet clause has not been triggered.
CytoDyn has registered to Fife 2point1 million shares which he is free to sell for $10 or more satisfying the loan in full. Or he can hold some or all. Do the parties now envision that the $10 price might present itself soon and that therefore CytoDyn filed the S3 ? We ARE awaiting CD12 TLD.
Let's play John Nash's strategic game.
Besides the above let's add all those factors already know including the application was made to NASDAQ and that a letter was sent from NASDAQ to Mulholland that the only remaining requirement was the stockholder equity requirement. Let's assume, and I think there is no serious question of this, that the satisfaction and removal of the Fife debt would give CytoDyn the necessary stock holder equity to up lift to NASDAQ.
Now what happens if any number of things happen?
A) CD12 reads out pushing the price above $10. Loan is satisfied. CYDY up lists. Shorts forced to cover. Counterfeit (naked shorts) shares are exposed and washed out of the float. CytoDyn defeats 28 million short shares with zero new shares. Plus eliminates any counterfeit shares and exposes the crimes.
CD12 reads out positive but does not reach $10. Pick any number it does not matter. Shorts do not cover or or cover and resort higher and maybe with more shares. Any price it does matter lets go extreme. Price rises to $9 and is shorted to $3, rebounds to $5. Now Cytodyn either issues Fife an additional 2 million or so shares and satisfies the debt or sells enough to a new investor to gain stock holder equity for NASDAQ up lists and the above result at the cost of 2 million shares dilution vs 28 million short and unknown number of counterfeit shares.
C) Prior to readout CytoDyn receives an OWS grant purchase order and payment for product, partnership venture payment, or other investment of an amount that satisfies NASDAQ for up list. Same result as A above.
D) CytoDyn Releases CD12 positive with the price action of shorting the News. CytoDyn surprise up lists to AMEX. Same result as A.
E) CytoDyn surprise up lists to AMEX mercifully forcing legitimate shorts to cover and exposing any criminals that conterfeited shares and washing them out of the float. Then releasing positive CD12 allowing legitimate former shorts to recover losses by going long CYDYD.
F) Independent of any positive catalyst as in C CytoDyn sells enough stock to gain NASDAQ up list before positive CD12 result PR. Same optimal result as E above but much more difficult to do.
G) CD12 results released not good. Shorts hammer CYDY stock. CYDY issues 20 millions of shares at a lower price gaining NASDAQ forcing shorts to cover this time making bank but CytoDyn removes any counterfeit shares from the float and moves forward in with the HIV BLA ...gains approval there and moves forward in NASH, Cancer and others.
- This is a fall back position that I personally think has a low mathematical probability due to all the known factors.
However, and this is just my investment style and is not advice especially for any other than a long term investor, this result might be the most advantageous result to establish or add to a long term investment in CYDY if one has confidence in the HIV indication.
Based on the HIV indication market value, comparables in the industry and the strength of the data in HIV, I place a current fundamental value of CYDY at a $7 billion of greater market cap or $8.75/share on a fully diluted basis for HIV potential alone before even filing the BLA, actual progress such as accepting the BLA and eventual approval would punch that number geometrically higher. However I believe CytoDyn will need to up list to NASDAQ or AMEX initially to attain that in the short term.
If they are paying attention in Vancouver and I think they are very on the ball and focused in the Game then an Exchange Up List is smouldering in the Volcano. ”
“ If there is no default on the loan from Fife the rachet clause is no triggered. The loan is not in default. The rachet clause has not been triggered.
CytoDyn has registered to Fife 2point1 million shares which he is free to sell for $10 or more satisfying the loan in full. Or he can hold some or all. Do the parties now envision that the $10 price might present itself soon and that therefore CytoDyn filed the S3 ? We ARE awaiting CD12 TLD.
Let's play John Nash's strategic game.
Besides the above let's add all those factors already know including the application was made to NASDAQ and that a letter was sent from NASDAQ to Mulholland that the only remaining requirement was the stockholder equity requirement. Let's assume, and I think there is no serious question of this, that the satisfaction and removal of the Fife debt would give CytoDyn the necessary stock holder equity to up lift to NASDAQ.
Now what happens if any number of things happen?
A) CD12 reads out pushing the price above $10. Loan is satisfied. CYDY up lists. Shorts forced to cover. Counterfeit (naked shorts) shares are exposed and washed out of the float. CytoDyn defeats 28 million short shares with zero new shares. Plus eliminates any counterfeit shares and exposes the crimes.
CD12 reads out positive but does not reach $10. Pick any number it does not matter. Shorts do not cover or or cover and resort higher and maybe with more shares. Any price it does matter lets go extreme. Price rises to $9 and is shorted to $3, rebounds to $5. Now Cytodyn either issues Fife an additional 2 million or so shares and satisfies the debt or sells enough to a new investor to gain stock holder equity for NASDAQ up lists and the above result at the cost of 2 million shares dilution vs 28 million short and unknown number of counterfeit shares. C) Prior to readout CytoDyn receives an OWS grant purchase order and payment for product, partnership venture payment, or other investment of an amount that satisfies NASDAQ for up list. Same result as A above.
D) CytoDyn Releases CD12 positive with the price action of shorting the News. CytoDyn surprise up lists to AMEX. Same result as A.
E) CytoDyn surprise up lists to AMEX mercifully forcing legitimate shorts to cover and exposing any criminals that conterfeited shares and washing them out of the float. Then releasing positive CD12 allowing legitimate former shorts to recover losses by going long CYDYD.
F) Independent of any positive catalyst as in C CytoDyn sells enough stock to gain NASDAQ up list before positive CD12 result PR. Same optimal result as E above but much more difficult to do.
G) CD12 results released not good. Shorts hammer CYDY stock. CYDY issues 20 millions of shares at a lower price gaining NASDAQ forcing shorts to cover this time making bank but CytoDyn removes any counterfeit shares from the float and moves forward in with the HIV BLA ...gains approval there and moves forward in NASH, Cancer and others.
- This is a fall back position that I personally think has a low mathematical probability due to all the known factors.
However, and this is just my investment style and is not advice especially for any other than a long term investor, this result might be the most advantageous result to establish or add to a long term investment in CYDY if one has confidence in the HIV indication.
Based on the HIV indication market value, comparables in the industry and the strength of the data in HIV, I place a current fundamental value of CYDY at a $7 billion of greater market cap or $8.75/share on a fully diluted basis for HIV potential alone before even filing the BLA, actual progress such as accepting the BLA and eventual approval would punch that number geometrically higher. However I believe CytoDyn will need to up list to NASDAQ or AMEX initially to attain that in the short term.
If they are paying attention in Vancouver and I think they are very on the ball and focused in the Game then an Exchange Up List is smouldering in the Volcano. ”
2
